合成MRI预测不同乳腺癌亚型新辅助化疗后病理完全缓解的效用
本研究回顾性纳入37例患者39个乳腺癌病灶,评估新辅助化疗前合成MRI定量参数预测病理完全缓解(pCR)的价值。多因素分析显示化疗前T2弛豫时间标准差(SD of Pre-T2)是pCR的独立预测因子,AUC为0.829,最佳截断值11.5时敏感度71.4%、特异度80%、准确率76.3%。作者认为该参数有预测潜力,但结果属初步,需进一步验证。
要点
- 化疗前合成MRI的SD of Pre-T2是pCR独立预测因子,AUC 0.829。
- SD of Pre-T2截断值11.5时,敏感度71.4%、特异度80%、准确率76.3%。
- 该参数有望辅助新辅助化疗前筛选可能pCR的乳腺癌患者。
局限性
- 回顾性研究设计。
- 样本量较小(37例患者39个病灶)。
- 作者指出结果为初步,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To evaluate the usefulness of synthetic magnetic resonance imaging (MRI) performed before the initiation of neoadjuvant chemotherapy (NAC) in predicting whether breast cancers can achieve a pathological complete response (pCR) after the completion of NAC.
MATERIALS AND METHODS: This retrospective study investigated 37 consecutive patients with 39 breast cancers (pCR: 14, and non-pCR: 25) who underwent dynamic contrast-enhanced (DCE)-MRI and synthetic MRI before the initiation of NAC. Using synthetic MRI images, quantitative values (T1 and T2 relaxation times, proton density [PD] and their standard deviations [SD]) were obtained in breast lesions, before (Pre-T1, Pre-T2, Pre-PD, SD of Pre-T1, SD of Pre-T2, SD of Pre-PD) and after (Gd-T1, Gd-T2, Gd-PD, SD of Gd-T1, SD of Gd-T2, SD of Gd-PD) contrast agent injection. The aforementioned quantitative values and several morphological features that were identified on DCE-MRI were compared between pCR and non-pCR.
RESULTS: Multivariate analyses revealed that the SD of Pre-T2 (p=0.038) was significant and was an independent predictor of pCR, with an area under the receiver operating characteristics curve of 0.829. The sensitivity, specificity, and accuracy of the SD of Pre-T2 with an optimal cut-off value of 11.5 were 71.4%, 80%, and 76.3%, respectively.
CONCLUSIONS: The SD of Pre-T2 obtained from synthetic MRI was used successfully to predict those breast cancers that would achieve a pCR after the completion of NAC; however, these results are preliminary and need to be verified by further studies.
引用
- Matsuda, Fukuyama, Matsuda, et al. Utility of synthetic MRI in predicting pathological complete response of various breast cancer subtypes prior to neoadjuvant chemotherapy. Clin Radiol. 2022. PMID: 36055826. doi:10.1016/j.crad.2022.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。